2009
Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study. Clinical Genitourinary Cancer 2009, 7: e58-e65. PMID: 19815483, DOI: 10.3816/cgc.2009.n.025.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaMulticenter phase I/II studyPhase I/II studyStage IV renal cell carcinomaPF-3512676II studyCell carcinomaAntitumor activityAdvanced metastatic renal cell carcinomaToll-like receptor 9 agonistMetastatic renal cell carcinomaAdvanced renal cell carcinomaLocal injection site reactionsPhase IGrade 3 fatigueGrade 4 AEsModest antitumor activityObjective response rateDose-limiting toxicityFlu-like symptomsInjection site reactionsReceptor 9 agonistSingle-agent treatmentPhase II expansionOpen label
2005
Bladder cancer. Clinical practice guidelines in oncology.
Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2005, 3: 4-5, 19-34. PMID: 19813320.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Transitional CellChemotherapy, AdjuvantCystectomyHumansNeoplasm StagingPrognosisUrinary Bladder NeoplasmsConceptsUrothelial tumorsCombined-modality approachIndividual patient's likelihoodClinical practice guidelinesStage of diseaseSpectrum of diseaseRange of prognosesCategories of diseaseUrothelial tractExtensive diseaseMetastatic diseaseStandard therapyMost recurrencesNew lesionsPatient's likelihoodOrgan preservationImproved outcomesMolecular stagingPractice guidelinesSurgical proceduresRadiation therapyGuide managementNew agentsAdvanced stageNew treatments